Daniel Pella, Milan Remko
Perindopril represents long-acting angiotensin converting enzyme inhibitor (ACE) with high affinity to the tissue ACE, capable to decrease level of angiotensin II and increase accessibility of bradykinin. Strong evidence based medicine confirmed its efficacy and safety not only in arterial hypertension therapy but all forms of coronary artery disease as well, including chronic heart failure. Perindopril power is multiplied by indapamide – when prescribed in combination it is considered for the golden standard of primary and secondary stroke prevention (studies PROGRESS and HYVET). The listed combination is highly effective in secondary prevention of cardiovascular events in patients with diabetes type 2 (study ADVANCE). Moreover, it brings excellent safety and significantly better compliance with treatment when administered in the original fixed combination of perindopril arginine/indapamide.